Press Release
19 November 2026 13:00:00 CET

Prostatype Genomics prepares supplementary submission in Medicare review following meeting with MolDX working group

Prostatype Genomics AB held the working meeting with the working group of Medicare's MolDX program announced on October 9, 2026. At the meeting, the working group requested additional information on one issue previously discussed as part of the U.S. Medicare coverage review for Prostatype®. The company is preparing its supplementary information and expects to submit it during the week of November 23–29 (week 48).

At the meeting, the working group and the company reviewed the questions that Prostatype Genomics answered in writing in October. Medicare's MolDX program is reviewing the application under the existing coverage framework for prognostic genomic tests for localized prostate cancer.

"The meeting clarified what supplementary information the working group is requesting, and the review continues to move forward. We have been working on our response since the meeting and are now focused on finalizing it," says Fredrik Rickman, CEO of Prostatype Genomics.

The timing of a final decision remains uncertain. The company will update the market when further relevant information about the review becomes available.

For further information, please contact

Fredrik Rickman, CEO of Prostatype Genomics AB
Phone: +46 730 49 77 01
Email: fredrik.rickman@prostatypegenomics.com

Certified Adviser
The company's Certified Adviser is Tapper Partners AB.
Phone: +46 70 440 10 98
Email: ca@tapperpartners.se